PIM1 anticorps (Internal Region)

N° du produit ABIN6264220

Détail du produit anti-PIM1 anticorps

Antigène: PIM1 (Pim-1 Oncogene (PIM1))

Épitope: Internal Region

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PIM1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Specificité: Pim-1 Antibody detects endogenous levels of total Pim-1.

Homologie: Pig,Bovine,Horse,Sheep,Rabbit,Dog,Chicken

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human Pim-1, corresponding to a region within the internal amino acids.

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Stable for 12 months from date of receipt.

Date de péremption: 12 months

Détails sur PIM1

Antigène: PIM1 (Pim-1 Oncogene (PIM1))

Autre désignation: PIM1 (PIM1 Produits)

Synonymes: anticorps PIM, anticorps Pim-1, anticorps PIM1, anticorps pim, anticorps pim-1, anticorps pim3, anticorps Pim-1 proto-oncogene, serine/threonine kinase, anticorps proviral integration site 1, anticorps Pim-1 proto-oncogene, serine/threonine kinase L homeolog, anticorps PIM1, anticorps Pim1, anticorps pim1, anticorps pim1.L

Sujet:

Description: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Gene: PIM1

Poids moléculaire: 50kDa

ID gène: 5292

UniProt: P11309

Pathways: Glycosaminoglycan Metabolic Process